IDEAYA Biosciences Beheer

Beheer criteriumcontroles 1/4

De CEO IDEAYA Biosciences is Yujiro Hata, benoemd in Jun2015, heeft een ambtstermijn van 9.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 6.00M, bestaande uit 10% salaris en 90% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.78% van de aandelen van het bedrijf, ter waarde € 17.32M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.9 jaar en 6 jaar.

Belangrijke informatie

Yujiro Hata

Algemeen directeur

US$6.0m

Totale compensatie

Percentage CEO-salaris	10.0%
Dienstverband CEO	9.4yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	1.9yrs
Gemiddelde ambtstermijn bestuur	6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Yujiro Hata's beloning veranderd ten opzichte van IDEAYA Biosciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$178m
Jun 30 2024	n/a	n/a	-US$154m
Mar 31 2024	n/a	n/a	-US$129m
Dec 31 2023	US$6m	US$598k	-US$113m
Sep 30 2023	n/a	n/a	-US$103m
Jun 30 2023	n/a	n/a	-US$74m
Mar 31 2023	n/a	n/a	-US$68m
Dec 31 2022	US$3m	US$570k	-US$59m
Sep 30 2022	n/a	n/a	-US$53m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$55m
Dec 31 2021	US$4m	US$544k	-US$50m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	n/a	n/a	-US$30m
Mar 31 2021	n/a	n/a	-US$31m
Dec 31 2020	US$2m	US$510k	-US$34m
Sep 30 2020	n/a	n/a	-US$40m
Jun 30 2020	n/a	n/a	-US$46m
Mar 31 2020	n/a	n/a	-US$44m
Dec 31 2019	US$2m	US$457k	-US$42m
Sep 30 2019	n/a	n/a	-US$40m
Jun 30 2019	n/a	n/a	-US$42m
Mar 31 2019	n/a	n/a	-US$38m
Dec 31 2018	US$2m	US$420k	-US$34m

Compensatie versus markt: De totale vergoeding ($USD 6.00M ) Yujiro } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.63M ).

Compensatie versus inkomsten: De vergoeding van Yujiro is gestegen terwijl het bedrijf verliesgevend is.

CEO

Yujiro Hata (50 yo)

9.4yrs

Tenure

US$5,995,440

Compensatie

Mr. Yujiro S. Hata serves as an Independent Director at Enanta Pharmaceuticals, Inc. since August 29, 2021. He is a Co-Founder of IDEAYA Biosciences, Inc. and has been its Chief Executive Officer, Presiden...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Yujiro Hata	President	9.4yrs	US$6.00m	0.78% € 17.3m
Andres Briseno	Principal Accounting Officer	3.8yrs	US$1.41m	0.028% € 626.6k
Michael White	Chief Scientific Officer	3yrs	US$2.76m	geen gegevens
Darrin Beaupre	Chief Medical Officer	2yrs	US$1.81m	0% € 0
Paul Barsanti	Chief Technology Officer	1.8yrs	geen gegevens	geen gegevens
Douglas Snyder	Senior VP & General Counsel	less than a year	geen gegevens	geen gegevens
Francine Zelaya	Vice President & Head of Human Resources	less than a year	geen gegevens	geen gegevens
Mick O'Quigley	Chief of Staff & Clinical Development	2.7yrs	geen gegevens	geen gegevens
Daniel Simon	Chief Business Officer	less than a year	geen gegevens	geen gegevens
Stu Dorman	Chief Commercial Officer	no data	geen gegevens	geen gegevens

1.9yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 30J wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yujiro Hata	President	9.4yrs	US$6.00m	0.78% € 17.3m
Wendy Yarno	Independent Director	4.9yrs	US$358.02k	0% € 0
Jeffrey Stein	Independent Director	9.1yrs	US$363.02k	0.0050% € 109.3k
Susan Kelley	Independent Director	3.8yrs	US$349.52k	0% € 0
Frank McCormick	Chair of Scientific Advisory Board	5.8yrs	geen gegevens	geen gegevens
Scott William Morrison	Independent Director	6.3yrs	US$364.52k	0% € 0
Catherine Mackey	Independent Director	2.6yrs	US$350.52k	0% € 0
Trey Ideker	Member of Scientific Advisory Board	8.5yrs	geen gegevens	geen gegevens
William Sellers	Member of Scientific Advisory Board	5.8yrs	geen gegevens	geen gegevens
Elizabeth Swisher	Member of Scientific Advisory Board	8.5yrs	geen gegevens	geen gegevens
Terry Rosen	Independent Chairman of the Board	8.8yrs	US$369.52k	0.019% € 417.5k
Malcolm Hampton	Independent Director	4.4yrs	US$349.52k	0% € 0

6.0yrs

Gemiddelde duur

67.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 30J wordt beschouwd als ervaren (gemiddelde ambtstermijn 6 jaar).

IDEAYA Biosciences Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer

IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel

IDEAYA Biosciences, Inc Announces Resignation of Jason Throne as Chief Legal Officer and Secretary, Effective July 11, 2024

IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024

IDEAYA Biosciences, Inc., Annual General Meeting, May 31, 2024

IDEAYA Biosciences, Inc. Announces Resignation of Paul A. Stone as Chief Financial Officer

Recent updates

IDEAYA Biosciences, Inc. Appoints Stu Dorman as Chief Commercial Officer

New minor risk - Revenue size

IDEAYA Biosciences, Inc. Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors

IDEAYA Biosciences, Inc. Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024

IDEAYA Biosciences, Inc. Appoints Douglas B. Snyder as Senior Vice President, General Counsel

First half 2024 earnings released: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)

IDEAYA Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $263.000016 million.

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 3000E Value Index

IDEAYA Biosciences, Inc Announces Resignation of Jason Throne as Chief Legal Officer and Secretary, Effective July 11, 2024

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer

IDEAYA Biosciences, Inc. Announces Clinical Program Updates for Ide397 A Potential First-In-Class Phase 2 Mat2a Inhibitor Targeting MTAP-Deletion Solid Tumors

IDEAYA Biosciences, Inc. Announces Results for darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma At Asco and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study

IDEAYA Biosciences, Inc. Appoints Daniel A. Simon as Chief Business Officer, Effective August 2024

First quarter 2024 earnings released: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)

IDEAYA Biosciences, Inc., Annual General Meeting, May 31, 2024

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Full year 2023 earnings released: US$1.96 loss per share (vs US$1.42 loss in FY 2022)

New major risk - Shareholder dilution

IDEAYA Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $350 million.

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.46 loss per share (vs US$0.04 profit in 3Q 2022)

IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline

New minor risk - Share price stability

IDEAYA Biosciences, Inc. Announces Resignation of Paul A. Stone as Chief Financial Officer

IDEAYA Biosciences, Inc. Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo) Adjuvant Uveal Melanoma

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.50 loss per share (vs US$0.57 loss in 2Q 2022)

IDEAYA Biosciences, Inc. Appoints Andres Ruiz Briseno as Principal Accounting Officer

New major risk - Shareholder dilution

IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types

First quarter 2023 earnings released: US$0.49 loss per share (vs US$0.36 loss in 1Q 2022)

Full year 2022 earnings released: US$1.42 loss per share (vs US$1.41 loss in FY 2021)

IDEAYA Biosciences, Inc. Announces Darovasertib Phase 2 Initiation in Neoadjuvant and Adjuvant Uveal Melanoma and Guidance for Clinical Data Update in Metastatic Uveal Melanoma

IDEAYA Biosciences, Inc. Announces Board Appointments

IDEAYA Biosciences, Inc Announces Submission of IND Application to the U.S. FDA for PARG Development Candidate IDE161

IDEAYA Biosciences, Inc. Appoints Darrin M. Beaupre as Chief Medical Officer to Lead Clinical Development of Expanding Clinical Pipeline

Third quarter 2022 earnings released: EPS: US$0.04 (vs US$0.31 loss in 3Q 2021)

IDEAYA Biosciences, Inc. Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors

IDEAYA Biosciences, Inc. Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma

IDEAYA Biosciences, Inc. Announces First-Patient-In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in (Neo)Adjuvant Uveal Melanoma

IDEAYA Announces Achievement of First Milestone in Ongoing Collaboration with GSK for Potential First-In-Class Pol Theta Helicase Inhibitor Development Candidate

Second quarter 2022 earnings released: US$0.57 loss per share (vs US$0.33 loss in 2Q 2021)

IDEAYA Biosciences, Inc. Announces Clinical Trial Collaboration with Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors

IDEAYA Biosciences, Inc. Announces Development Candidate Nomination of Potential First-In-Class Pol Theta Helicase Inhibitor in Collaboration with GSK

IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell 2000 Growth Index

IDEAYA Biosciences, Inc. Appoints Catherine Mackey to its Board of Directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

IDEAYA Biosciences, Inc. Advances First-in-Class PARG Development Candidate, IDE161, into IND-Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License

IDEAYA Biosciences, Inc. Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal Melanoma

Director Yujiro Hata has joined 3rd company board

IDEAYA Announces Dose Expansion in Phase 1/2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort

New 90-day high: €17.80

IDEAYA Biosciences, Inc. Appoints Susan L. Kelley to its Board of Directors

New 90-day high: €16.40

IDEAYA Biosciences, Inc. Announces Appointment of Matthew Maurer as Head of Clinical Oncology and Medical Affairs

New 90-day high: €16.30

Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology Industry

IDEAYA Biosciences, Inc. Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDA

IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor

New 90-day low: €10.10

Nasdaq Biotechnology Index Selects IDEAYA Biosciences, Inc

New 90-day high: €12.70

IDEAYA Biosciences, Inc. and Pfizer Inc. Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations

IDEAYA Biosciences, Inc. Names Garret Hampton to the Nominating and Corporate Governance Committee

IDEAYA Biosciences, Inc. announced that it has received $19.999995 million in funding from Glaxosmithkline Intellectual Property (No.4) Limited

Analyse CEO-vergoeding

CEO

Tenure

Compensatie